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Abstract
Musculoskeletal fibromatosis remains a disease of unknown etiology. Surgical excision is the standard of care, but the
recurrence rate remains high. Superficial fibromatosis typically presents as subcutaneous nodules caused by rapid
myofibroblast proliferation followed by slow involution to dense acellular fibrosis. In this study, we demonstrate that
fibromatosis stem cells (FSCs) can be isolated from palmar nodules but not from cord or normal palm tissues. We found that
FSCs express surface markers such as CD29, CD44, CD73, CD90, CD105, and CD166 but do not express CD34, CD45, or
CD133. We also found that FSCs are capable of expanding up to 20 passages, that these cells include myofibroblasts,
osteoblasts, adipocytes, chondrocytes, hepatocytes, and neural cells, and that these cells possess multipotentiality to
develop into the three germ layer cells. When implanted beneath the dorsal skin of nude mice, FSCs recapitulated human
fibromatosis nodules. Two weeks after implantation, the cells expressed immunodiagnostic markers for myofibroblasts such
as a-smooth muscle actin and type III collagen. Two months after implantation, there were fewer myofibroblasts and type I
collagen became evident. Treatment with the antifibrogenic compound Trichostatin A (TSA) inhibited the proliferation and
differentiation of FSCs in vitro. Treatment with TSA before or after implantation blocked formation of fibromatosis nodules.
These results suggest that FSCs are the cellular origin of fibromatosis and that these cells may provide a promising model
for developing new therapeutic interventions.
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Introduction
Musculoskeletal fibromatosis is a condition that presents as
benign soft tissue tumors with an aggressive course. This disease
can be divided into superficial (fascial) and deep (musculoaponeu-
rotic) groups, and both share a common histopathological
appearance. The superficial group tumors are typically small,
slow-growing lesions and include palmar fibromatosis (Dupuyt-
ren’s disease) [1], plantar fibromatosis [2], penile fibromatosis
(Peyronie’s disease) [3], and infantile digital fibroma [4]. The
typical clinical picture of superficial fibromatosis involves the
formation of subcutaneous fibromatosis nodules that progress
slowly to involve the skin and deep structures or to form a cord,
which causes contractures. In contrast to the superficial group of
fibromatosis, the lesions of deep fibromatosis are often large, more
aggressive, and possible faster growing. Deep fibromatosis includes
aggressive fibromatosis (desmoid tumor) [5], infantile myofibro-
matosis, fibromatosis colli, and aggressive infantile fibromatosis.
The main components of fibromatosis are myofibroblasts,
which exhibit features of smooth muscle cells and fibroblasts
surrounded by abundant collagen material. a-Smooth muscle
actin (a-SMA) and type III collagen are specific markers of
myofibroblasts in fibromatosis [6;7]. Despite recent advances in
understanding the biochemical and cellular processes of fibroma-
tosis, the precursor cells of myofibroblasts and uncontrolled
growth behavior of fibromatosis remain elusive, and the
pathogenesis of fibromatosis remains unclear [6;8–11]. The main
treatment option for fibromatosis is surgical excision; fibromatosis
does not metastasize [12], but local regional control remains
challenging with excision alone because of a high local recurrence
rate [2;13–15].
Adult stem cells, like pluripotent stem cells, have the ability to
self-renew and to differentiate into multiple lineage cells including
bone, fat, cartilage [16], and nonmesenchymal tissues such as
neurons [17] and hepatocytes [18]. Stem cells are known to exist
in various tissues, although it is unclear whether stem cells can be
isolated from fibromatosis tissues. Palmar fibromatosis is the most
common type of fibromatosis and shares the same clinical course
with other fibromatosis [19], and we therefore conducted
experiments to isolate stem cells from palmar fibromatosis and
refer to these cells here as fibromatosis-derived stem cells (FSCs).
A hallmark of palmar fibromatosis is its clinical course, which is
divided into three stages [20]. The earliest proliferative stage is
characterized by nodule formation with hypercellular areas full of
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involutional stage, the hypercellular areas have fewer cells and the
expression of type I collagen increases. In the residual stage,
nodules are replaced by dense acellular fibrosis [21]. To our
knowledge, no animal model of fibromatosis nodules has been
reported. We postulated that a murine model of fibromatosis
nodule could be developed by implanting FSCs into the back of
nude mice. The characteristic properties of FSCs in this murine
model include their unique ability to recapitulate the natural
course of human palmar fibromatosis.
To identify an early nonsurgical treatment for fibromatosis
nodules before they progress to the stage where only surgical
excision can be applied, our group investigated the potential
antifibrogenic effect of trichostatin A (TSA), a histone deacetylase
inhibitor (HDACi). It has been reported that treating various
tumor cells with TSA can induce cell differentiation, cell apoptosis,
or necrosis. TSA is thought to have antifibrogenic potential by
inhibiting a-SMA [22] and has been tested as a promising
therapeutic agent in hepatic fibrosis [23]. However, the therapeu-
tic potential of TSA in treating fibromatosis has not been
investigated. In this study, we used our murine model to examine
the therapeutic effect of TSA on FSCs in vitro and in vivo.
Materials and Methods
Isolation and expansion method
This research followed the tenets of the Declaration of Helsinki.
Fibromatosis tissues were obtained from six patients receiving
excision for palmar fibromatosis after they provided written
informed consent (Table 1). The study protocol and written
informed consent forms were approved by the Institutional Ethics
Committee/Institutional Review Board of Taipei Veterans
General Hospital, Taiwan.
The tissues were washed repeatedly in phosphate-buffered
saline (PBS; Gibco BRL, Grand Island, NY); the fat tissues were
scraped off carefully, leaving only the nodule and cord portion of
the palmar fibromatosis tissues to be used in the experiment. The
tissues were collected by centrifugation and digested with 3 mg/ml
collagenase for 3 h. The nucleated cells were then plated at clonal
density and cultured in a-minimal essential medium (a-MEM,
Invitrogen, Carlsbad, CA) containing 10% fetal bovine serum
(FBS; Invitrogen; lot selected for rapid growth), 100 U/ml
penicillin (Invitrogen), 100 mg/ml streptomycin (Invitrogen), and
250 ng/ml amphotericin B (Invitrogen). The cells were fed every 2
days by changing to fresh growth medium and propagated every 4
days at a 1:5 split before cell growth reached 80% confluence.
To track the cellular fate of FSCs in our murine model of
fibromatosis nodules, FSCs were transduced with a lentiviral green
fluorescent protein (GFP) vector followed by antibiotic selection.
GFP-expressing FSCs delivered in growth factor-reduced Matrigel
(BD Biosciences, Bedford, MA) were injected subcutaneously into
nude mice, and the implants were harvested at the times indicated,
fixed in paraformaldehyde, and processed for paraffin sections.
Flow cytometric analysis
To analyze the cell surface expression of typical marker
proteins, FSCs were harvested in 5 mmol/l EDTA in PBS. Cells
were incubated with the following anti-human antibodies: CD34–
phycoerythrin (PE), CD73–PE (also referred to as SH3 and SH4),
CD90–fluorescein isothiocyanate (FITC, Becton Dickinson, San
Jose, CA), CD29–FITC, CD44–FITC, CD45–FITC (Beckman
Coulter, Krefeld, Germany), CD133–PE (Miltenyi Biotec, Ber-
gisch Gladbach, Germany), CD105–FITC(SH2), or CD166–
FITC (ImmunoKontact, AMS Biotechnology, Wiesbaden, Ger-
many). Mouse isotype antibodies (Becton Dickinson and Beckman
Coulter) were used as controls. Ten thousand labeled cells were
acquired and analyzed using a FACScan flow cytometry running
CellQuest software (Becton Dickinson).
Cell proliferation assay
The cytotoxicity effect of TSA on FSCs was measured with a
cell proliferation test kit using 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT, Sigma, St Louis, MO) to
determine the inhibitory concentrations (IC50-values) of TSA. The
cells were seeded at 2000 cells/well in a 96-well culture plate and
incubated with different concentrations of TSA (0, 10, 100, 200,
400, 600, 800, and 1000 nM). The absorbance after incubation
with MTT for 4 h at 37uCi n5 %C O 2 was measured with an
enzyme-linked immunosorbent assay (ELISA) plate reader after 7
days. Cell numbers were determined using the optical density
(OD) value at a test wavelength of 560 nm. The IC50-values were
determined and used as an indicator of proliferation inhibition.
Differentiation protocols
The FSCs from all donors were induced under the following
culture conditions. The non-stem cell lines 293T cells were used as
negative control cells [24].
(I) Osteogenic differentiation medium comprised a-MEM
supplemented with 10% FBS, 50 mg/ml ascorbate-2 phos-
phate (Nacalai, Kyoto, Japan), 10
28 M dexamethasone
(Sigma), and 10 mM b-glycerol phosphate (Sigma) [25].
(II) Adipogenic differentiation medium comprised a-MEM
supplemented with 10% FBS, 50 mg/ml ascorbate-2 phos-
phate, 10
27 M dexamethasone, 50 mg/ml indomethacin
Table 1. Details of the donors with palmar fibromatosis-derived stem cells.
Donor no. Age (years)/ gender Duration(months) Joint of Contracture Source of stem cells
1 69/female 7 MCP, PIP Nodule
2 83/male 5 MCP Nodule
3 49/male 4 MCP Nodule, Cord
4 85/male 7 MCP, PIP Nodule, Cord
5 46/male 10 MCP, PIP Nodule,
6 83/male 5 MCP Nodule
MCP joint: Metacarpalphalangeal joint.
PIP joint: Proximal interphalangeal joint.
doi:10.1371/journal.pone.0024050.t001
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10 mg/ml insulin (Sigma) [25].
(III) Cells were induced in a defined chondrogenic induction
medium comprising serum-free DMEM high-glucose
(DMEM-HG) supplemented with ITS
+ Premix (BD
Biosciences, Bedford, MA: 6.25 mg/ml insulin, 6.25 mg/
ml transferrin, 6.25 mg/ml selenious acid, 1.25 mg/ml
bovine serum albumin (BSA), 5.35 mg/ml linoleic acid),
10
27 M dexamethasone (Sigma), 50 mg/ml ascorbate-2-
phosphate (Sigma), and 10 ng/ml transforming growth
factor (TGF)-b1. The pelleted cells were incubated at 37uC
in 5% CO2. Within 12–24 h of incubation, the cells formed
an essentially spherical cluster that did not adhere to the
walls of the tube. The medium was changed every 3 days.
Cells were then used for histochemical staining and
immunofluorescence study after the morphological features
of differentiation appeared. Cells were washed with PBS,
fixed in 3.7% paraformaldehyde for 10 min at room
temperature, and stained with Alizarin red-S following
osteogenic differentiation to reveal osteogenic differentia-
tion. Cells treated under adipogenic and chondrogenic
culture conditions were stained with Oil red-O and Alcian
blue to show adipogenic and chondrogenic differentiation,
respectively. Type II collagen staining was identified by
immunohistochemistry [25].
(IV) To induce hepatogenic differentiation, cells at 5610
5 cells/
100-mm dish were serum deprived for 2 days, cultured in
a-MEM supplemented with 20 ng/ml epidermal growth
factor (EGF, Sigma) and 10 ng/ml basic fibroblast growth
factor (bFGF,Sigma), and then subjected to induction by a
2-step protocol. Differentiation was induced by treating
cells with step-1 differentiation medium comprising a-
MEM supplemented with 20 ng/ml hepatocyte growth
factor (Sigma), 10 ng/ml bFGF, and 0.61 g/l nicotinamide
(Sigma) for 7 days, followed by treatment with step-2
maturation medium, comprising a-MEM supplemented
with 20 ng/ml oncostatin M (R&D Systems), 1 mol/l
dexamethasone, and 50 mg/ml ITS
+ Premix (BD Biosci-
ences: 6.25 mg/ml insulin, 6.25 mg/ml transferrin, 6.25 mg/
ml selenious acid, 1.25 mg/ml BSA, 5.35 mg/ml linoleic
acid) for 7 days [18].
(V) To induce neural differentiation, cells at 3610
5 cells/100-
mm dish were pretreated with a-MEM supplemented with
10% FBS, 10% fetal calf serum, 10
23 M mercaptoethanol
(Sigma), and 10
27 M all-trans-retinoic acid (Sigma) for
24 h, and then deprived of serum for 5 days [17].
Reverse transcription (RT) and real-time polymerase
chain reaction (PCR) analysis
Total RNA was prepared using TRIzol reagent (Invitrogen,
Australia). For first-strand cDNA synthesis, random sequence
primers were used to prime RT reactions and synthesis was
performed using SuperScript
TM III Reverse Transcriptase (In-
vitrogen, Carlsbad, CA). cDNA was synthesized from total RNA
using M-MuLV reverse transcriptase. PCR was performed with
cDNA as the template in a 30-ml reaction mixture containing
specific primer pairs (Table 2). Negative controls were used for
each primer by replacing cDNA by distilled water on the one hand
and replacing cDNA by RNA in order to exclude contamination
with genomic DNA (Fig. S2). PCR was performed using Taq DNA
Polymerase Recombinant (Invitrogen), and each cycle comprised
the following steps: denaturation for 45 s at 94uC, annealing for
1 min at 51–58uC, and 90 s of elongation at 72uC. Glyceralde-
hyde-3-phosphate dehydrogenase (GAPDH) was used to normal-
ize input template cDNA to analyze relative gene expression. The
reaction products were resolved by electrophoresis on a 1.5%
agarose gel and visualized with ethidium bromide.
Real-time amplification of the genes was performed using the
ABI Assays on Demand primers
and SYBR greenH universal PCR
Master Mix on the ABI 7500 real-time PCR instrument according
to the manufacturer’s instructions (Applied Biosystems, Foster City,
CA). To check the efficiency of PCR amplification and cDNA
synthesis, GAPDH was used as an internal control (Table 3).
Analysis of the results was performed using the software supplied
with the machine using the DCT method.
In vivo murine model of fibromatosis nodule
The animal care and experimental protocols were in accor-
dance with the institutional animal welfare guidelines of Taipei
Veterans General Hospital. All procedures involving animals were
approved by the institutional animal care and use committee of
Taipei Veterans General Hospital (98-081). Matrigel implants
were used to injected the mice with benign tumor stem cells to
recapitulate benign tumors [26], and we used this method to
recapitulate the development of fibromatosis nodules. The
containment of cells within Matrigel in the implant helps entrap
the cells within the injection site. The murine model of
fibromatosis nodules was created by implantation of FSCs in 4–
6-week-old male athymic nu/nu mice. In brief, 1.0610
6 FSCs
suspended in 200 ml Matrigel were injected subcutaneously into
the back of the mouse, and each mouse received 4 injections.
Animals were sacrificed and the Matrigel implants were harvested
at 7, 14, 28, and 56 days. The Matrigel implants were fixed in
3.7% paraformaldehyde for immunohistochemistry and immuno-
fluorescence staining.
In previous studies, TSA was given subcutaneously at a dose of
0, 1, 2, or 5 mg/kg every day in murine models of retroperitoneal
neuroblastoma [27], arthritis [28], and endometriosis [29]. In the
current study, TSA (2 mg/kg body weight) dissolved in 40 mlo f
dimethyl sulfoxide (DMSO) was injected subcutaneously daily for
1 week. To maintain the integrity of the Matrigel implants, TSA
was injected subcutaneously between the Matrigel implants.
Immunohistochemistry and immunofluorescence
staining
Paraffin-embedded sections were deparaffinized in xylene,
dehydrated through graded alcohols from 100% to 70%, and
then rinsed in ddH2O to remove the organic solution. Antigen
retrieval was achieved by boiling the slides in 10 mM sodium
citrate buffer pH 6.0 at 99uC for 30 min. The slides were then
cooled to room temperature, rinsed in PBS, and blocked with 3%
H2O2; nonspecific staining was blocked with PBS containing 5%
heat-inactivated FBS for 30 min at room temperature. A mouse
monoclonal antibody against human type II collagen (Daiichi Fine
Chemical Co., Toyama, Japan) was used as the primary antibody.
Polymer–horseradish peroxidase (HRP, BioGenex, San Ramon,
CA) was used as the secondary antibody, and diaminobenzidine
(DAB; BioGenex) was applied until the color appeared. The
sections were counterstained with Harris hematoxylin (Sigma-
Aldrich, St. Louis, MO) and mounted. Sections of hematoxylin
and eosin (H&E)-stained Matrigel implants were observed on an
Olympus AX80 light microscope and the images were quantified
using ImageJ software.
For immunofluorescence staining, primary antibodies against a-
SMA (Sigma-Aldrich), type III collagen (Abcam, Cambridge,
UK), type I collagen (Abcam), glial fibrillary acidic protein (GFAP;
Recapitulation of Fibromatosis Nodule
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Cruz Biotechnology, Santa Cruz, CA), GFP (Abcam), and
albumin (Santa Cruz Biotechnology) were placed on slides at
appropriate dilutions. The sections were then incubated with
DyLight 594-conjugated goat anti-rabbit IgG, DyLight 488-
conjugated goat anti-rabbit IgG, DyLight 594-conjugated goat
anti-mouse IgG, or DyLight 488-conjugated donkey anti-goat IgG
secondary antibodies (all from Jackson ImmunoResearch Labora-
tories Inc., West Grove, PA). The sections were counterstained
with 4,6-diamidino-2-phenylindole (DAPI; Vector Labs, Burlin-
game, CA) for nuclear (blue) fluorescent staining.
Statistical analysis
All statistical analyses were performed using SAS statistical
software (version 6.12, SAS Institute, Cary, NC) or SPSS software
(version 8.0, SPSS, Chicago, IL). The results are presented as
mean 6 SD. The significance of differences between the
experimental and control groups was determined by analysis of
variance, and a p value,0.05 by Student’s t test was considered
significant.
Results
Isolation of FSCs by enzymatic digestion and plastic
adherence
Isolation of FSCs was based on the measures of enzyme
digestion and plastic adherence [25]. The cell mixture was
obtained by adding collagenases to tissues of palmar fibromatosis.
Enrichment of FSCs was achieved by removing nonadherent cells
when changing to fresh growth medium at 2-day intervals. The
FSCs were plastic adherent with spindle-shaped morphology
(Fig. 1A). The cells were propagated every 4 days at a 1:5 split
when they reached 80% confluence. The doubling times of FSCs
were estimated at 40–48 h at a seeding density of 4000 cells/cm
2.
The FSCs could be expanded in culture for up to 20 passages
while maintaining their proliferative and undifferentiated status in
the earliest passages. The rate of replication of the FSC cultures
plateaued after about 10 weeks after 40 population doublings (PD),
when subcultivation became impossible (Fig. 1B). The isolation
efficiency of FSCs was much higher in nodules compared with
cords or normal tissues obtained from the same palm (Table 1),
suggesting that the nodules contained more FSCs than the cords.
Flow cytometric analysis of FSCs
For phenotypic characterization of the FSCs, we first used flow
cytometry to examine the expression of different CD surface
antigens at passages 3 to 5. These cells from six individual donors
were consistently positive for several putative mesenchymal stem
cell (MSC) markers, such as CD29, CD44, CD73, CD90, CD105,
and CD166, but were negative for markers of early or differentiated
hematopoietic cells such as CD34, CD45, and CD133 (Fig. 1C).
These results suggested that FSCs expressed the same surface
markers as MSCs from bone marrow and other tissues.
Myofibroblast differentiation of FSCs
We first investigated whether FSCs differentiate into myofibro-
blasts in vitro by analyzing the expression of a-SMA and type III
collagen. Quantitative RT-PCR demonstrated that culturing FSCs
increased the expression of genes such as a-SMA, Col3A1, and
Col1A3 as the time of culture continued (Fig. 2A), suggesting
Table 2. Primers used for reverse transcription-polymerase chain reaction (RT-PCR) analysis.
Gene Sense primer Anti-sense primer
LPL GGTCGAAGCATTGGAATCCAG TAGGGCATCTGAGAACGAGTC
PPARc2 CCTATTGACCCAGAAAGCGATTC GCATTATGAGACATCCCCACTGC
OP CTAGGCATCACCTGTGCCATACC CAGTGACCAGTTCATCAGATTCATC
RUNX2 GTTTGTTCTCTGACCGCCTC CCAGTTCTGAAGCACCTGA
COL2A1 CCAGGACCAAAGGGACAGAAAG TTCACCAGGTTCACCAGGATTG
bIII-TUB CGAGACCTACTGCATCGACA GGGATCCACTCCACGAAGTA
NES TTCCCTTCCCCCTTGCCTAATACC TGGGCTGAGCTGTTTTCTACTTTT
AFP TGCAGCCAAAGTGAAGAGGGAAGA CATAGCGAGCAGCCCAAAGAAGAA
ALB TGCTTGAATGTGCTGATGACAGGG AAGGCAAGTCAGCAGGCATCTCATC
GAPDH ATATTGTTGCCATCAATGACC GATGGCATGGACTGTGGTCATG
LPL, lipoprotein lipase; PPARc, peroxisome proliferator-activated receptor-c; OP, osteopontin; RUNX2, runt-related transcription factor 2; COL2A1, a-1 type II collagen;
bIII-TUB, b-tubulin III; NES, nestin; AFP, a-fetoprotein; ALB, albumin; GAPDH, Glyceraldehyde-3-phosphate dehydrogenase.
doi:10.1371/journal.pone.0024050.t002
Table 3. Primers used for real-time reverse transcription-polymerase chain reaction analysis.
Gene Primer length Tm Sense primer Anti-sense primer
Col1A2 20 51.78 GACATGCTCAGCTTTGTGGA CTTTCTCCACGTGGTCCTCT
Col3A1 20 50.2 GGAGAATGTTGTGCAGTTTG AGGACCAGTAGGGCATGA
a-SMA 20 53.7 CATCATGCGTCTGGATCTGG GGACAATCTCACGCTCAGCA
GAPDH 21 52.57 ATATTGTTGCCATCAATGACC GATGGCATGGACTGTGGTCATG
Col1A2, a2 type I collagen; Col3A1, a1 type III collagen; a-SMA, a-smooth muscle actin; GAPDH, Glyceraldehyde-3-phosphate dehydrogenase.
doi:10.1371/journal.pone.0024050.t003
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PLoS ONE | www.plosone.org 4 August 2011 | Volume 6 | Issue 8 | e24050Figure 1. Characterization of FSCs. (A) Morphology of FSCs 1 and 4 days after seeding. Bars=200 mm. (B) Proliferation curve of FSCs from
different donors. Cumulative population doubling curves vs. time of in vitro culture are based on 3- or 4-day split passages of FSCs at a 1:5 ratio. (C)
Flow cytometric analysis of the surface protein profile of FSCs at passage 4; the dashed line represents the isotype IgG and the solid line indicates the
antibody. All experiments were repeated with FSCs from three different donors.
doi:10.1371/journal.pone.0024050.g001
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studied whether fibrosis-related growth factors, such as bFGF,
EGF, and TGF-b1 [30–32], induced myofibroblast differentiation.
All of the growth factors examined here induced myofibroblast
differentiation, and TGF-b1 had the strongest fibrogenic effect
(Fig. 2B). These results indicated the myofibroblast differentiation
potential of FSCs and the important role of FSCs in the
development of fibromatosis.
Differentiation potential of FSCs
To study the differentiation potential of FSCs further, FSCs
were induced to differentiate along the hepatic, neuroglial,
adipogenic, osteogenic, and chondrogenic lineages. Hepatic
differentiation was demonstrated clearly by albumin staining at 2
weeks of differentiation (Fig. 3A). Significantly greater expression
of albumin and a-fetoprotein genes was detected at 2 weeks of
differentiation compared with the control culture condition
(Fig. 3A). Neuroglial differentiation was demonstrated clearly by
the accumulation of b-tubulin III and GFAP at 2 weeks of
differentiation (Fig. 3B). Significantly greater expression of b-
tubulin III and nestin genes was detected at 2 weeks of
differentiation compared with the control culture condition
(Fig. 3B). Adipogenic differentiation was demonstrated clearly by
the accumulation of Oil red-O-stained lipid vesicles at 3 weeks of
differentiation, whereas cells cultured in control growth medium
were negative for Oil red-O staining (Fig. 3C). Significantly
greater expression of peroxisome proliferator-activated receptor-c
(PPARc) and lipoprotein lipase (LPL) genes was detected at 3
weeks of differentiation compared with the control culture
condition (Fig. 3C). Osteogenic differentiation was demonstrated
in cells stained positive for Alizarin red-S at 2 and 3 weeks of
osteogenic differentiation, whereas cells grown in control growth
medium were not stained by Alizarin red-S (Fig. 3D). RT-PCR
demonstrated further the expression of osteopontin (OP) and runt-
related transcription factor 2 (RUNX2) at 14 days of osteogenic
differentiation, whereas cells grown in control medium did not
express OP (Fig. 3D). At 3 weeks of chondrogenic differentiation,
Alcian blue staining and type II collagen immunohistochemistry
revealed depositions of glycosaminoglycan and type II collagen in
pelleted cultured cells, respectively (Fig. 3E). RT-PCR analysis also
revealed the expression of cartilage oligomeric protein (COMP)
and COL2A1 genes (Fig. 3E). All of these results demonstrated the
differentiation potential of FSCs.
Formation of fibromatosis-like nodules by FSCs in
immunodeficient mice
To determine whether FSCs can form fibromatosis nodules in
our murine model, the cells were delivered in Matrigel and
implanted subcutaneously beneath the dorsal skin of nude mice for
56 days. Staining of the sections showed an increase in the
accumulation of a-SMA and type III collagen, myofibroblast
density, and vessel formation at 7 and 14 days (Fig. 4A, 4B). This
was similar to the histological picture of the composition of nodules
in the proliferative phase of human fibromatosis (Fig. S1). By
contrast, Matrigel alone or bone marrow MSCs implanted in
Matrigel did not form fibromatosis nodules and seemed to be
decomposing (data not shown).The next objective was to determine
whether FSCs recapitulated the involutional and residual phases of
fibromatosis nodules. Staining of the sections with H&E and
immunofluorescence from 28 to 56 days after implantation of
Matrigel showed decreased myofibroblast density and increased
accumulation of type I collagen (Fig. 4A, 4B). This was consistent
with the reduced number of cells seen during the involution of
human fibromatosis nodules (Fig. S1). A gross view showed that the
Matrigel was becoming firm and opaque over time because the
Matrigel was replaced by type I collagen (Fig. 4A). The results of
western blotting for a-SMA and types III and I collagen were also
consistent with the immunofluorescence findings (Fig. 4C).
Differentiation of GFP-labeled FSCs into myofibroblasts
in vivo
To examine the cellular fate of FSCs in our murine model of
fibromatosis nodules, FSCs were transduced with a lentiviral
vector carrying the GFP gene (Fig. 5A). Costaining for the GFP-
tracking marker and myofibroblast markers 14 days after
implantation with Matrigel showed that GFP-labeled cells were
also positive for a-SMA and type III collagen (Fig. 5B, 5C). These
data indicated that the newly formed fibromatosis nodules were
derived from human FSCs.
Figure 2. Confluence-induced and growth factor-induced fibrogenic potential of FSCs. (A) FSCs were seeded at 4000 cells/cm
2, cultured,
and harvested after 7, 14, and 21 days, and the relative mRNA levels of a-SMA, collagen type III, and collagen type I were evaluated by quantitative
RT-PCR. (B) FSCs were treated with or without (Control) 10 ng/ml bFGF, 10 ng/ml EGF, or 10 ng/ml TGF-b1 for 7 days. Cells were harvested, and the
relative mRNA levels of a-SMA, collagen type III and collagen type I was evaluated by quantitative RT-PCR. All transcript levels were normalized to
GAPDH transcript production. Statistical significance is presented as **, p,0.01 compared with the other groups. All experiments were repeated with
FSCs from three different donors.
doi:10.1371/journal.pone.0024050.g002
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PLoS ONE | www.plosone.org 6 August 2011 | Volume 6 | Issue 8 | e24050Figure 3. Differentiation potential of FSCs. (A) Hepatic potential of FSCs. Microscopic images showing morphology and albumin staining of
hepatic differentiation at 14 days (HIM). Expression of hepatic genes after 14 days of hepatic differentiation (HIM) in FSCs as demonstrated by RT-PCR.
(B) Neuroglial potential of FSCs. Microscopic images showing b-tubulin III and GFAP staining for neuroglial differentiation at 14 days (NIM). Expression
of neuroglial genes after 14 days of neuroglial differentiation (NIM) in FSCs as demonstrated by RT-PCR. (C) Adipogenic potential of FSCs. Microscopic
images showing Oil red-O staining of control cells (Con) and adipogenic differentiation at 21 days (AIM). Expression of adipogenic genes after 7 days
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in vitro
Because TSA is a fibrogenic inhibitor, we next assessed the
effects of TSA on the proliferation and fibrogenesis of FSCs. The
IC50-value was 400–600 nM (Fig. 6A). Quantitative RT-PCR
showed that treatment for 14 days with TSA at concentrations that
did not induce cytotoxicity inhibited the expression of a-SMA,
Col3A1, and Col1A3 mRNAs in a dose-dependent manner
(Fig. 6B). Immunofluorescence also demonstrated that TSA
inhibited the expression of a-SMA and type III collagen (Fig. 6C,
6D). These data suggested that TSA suppressed the proliferation
and myofibroblast differentiation of FSCs in vitro (Fig. 6E).
Inhibition by TSA of the ability of FSCs to form
fibromatosis-like nodules in immunodeficient mice
To determine the effect of TSA on the ability of FSCs to form
fibromatosis nodules in this murine model, FSCs were treated with
TSA before or after implantation with Matrigel. TSA decreased
the expression of a-SMA and the accumulation of type III and
type I collagen compared with the control condition (Fig. 7A–7H).
The Matrigel was not as firm, rounded and was going to be
decomposed compared with the control condition (Fig. 7A–7H).
These data suggested that TSA blocked the formation of
fibromatosis nodules by FSCs in vivo.
Discussion
The etiology of fibromatosis remains unclear and this disease
has a high recurrence rate after surgery [14]. In our current study,
we successfully isolated FSCs from tissues obtained from
fibromatosis of the palm. The FSCs adopted a fibroblastic-like
morphology and shared the surface protein profile of MSCs, and
these cells could be subcultured up to 20 passages without
significant loss of replication capacity. More importantly, FSCs
expressed myofibroblast markers after being maintained in growth
culture for a long time. FSCs are able to self-renew and
differentiate along lineages including ectodermal, mesodermal,
and endodermal lineages and therefore can be recognized as
multipotent-like stem cells. The GFP-tracking system showed that
the implanted FSCs formed fibromatosis nodules and differenti-
ated into myofibroblasts in vivo. These results demonstrate that
FSCs are the cellular precursors of fibromatosis. Although most
isolated adult stem cells are excellent sources for tissue regener-
ation, these FSCs should be considered therapeutic targets or a
promising animal model for the development of new therapeutic
interventions.
At present, there is no animal model that represents the
phenotypes and clinical course of human fibromatosis. We
successfully developed a murine model of fibromatosis nodules
by implanting human FSCs into immunodeficient mice. This
model reflected the morphological phenotypes of fibromatosis
nodules and recapitulated the clinical course of fibromatosis,
including the proliferative, involutional, and residual stages.
Because the GFP-tracking system showed that the myofibroblasts
that synthesized a-SMA and type III collagen in nodules were
derived from FSCs, which did not originally express a-SMA and
type III collagen, our data suggest that this benign tumor can be
recapitulated by these stem cells. Similar evidence has been
reported in infantile hemangioma, which has been shown to
develop after implantation of hemangioma stem cells in a murine
model [26]. What makes our in vivo model unique is that only a
small number of FSCs suspended in Matrigel were needed to
produce the fibromatosis lesions in the absence of exogenous
growth factors or supplements. This implies that there may be a
genetic or epigenetic control in the FSCs that directs the cells to
recapitulate fibromatosis.
Cell aggregation can induce differentiation into a variety of
lineages such as osteogenesis, chondrogenesis, hepatic differenti-
ation, neural differentiation, and insulin-producing cell differen-
tiation [33;34], and this may help explain why FSCs spontaneously
differentiated into myofibroblasts. FSCs cultured in growth
medium formed aggregates, which may help to induce myofibro-
blast differentiation. However, the detailed mechanisms underly-
ing this aggregation-induced differentiation remain elusive.
The existence of FSCs in fibromatosis nodules may explain the
high recurrence rate of fibromatosis after excision. One possible
explanation is that niches generated by tumor excision stimulate
proliferation of stem cells [35]. Although myofibroblasts exist in
normal and pathological tissues, the cellular origin of fibromatosis
tissues remains unclear. Local mesenchymal cells [36] undergoing
epithelial-to-mesenchymal transformation (EMT) [37] are thought
to be the cellular origin of pathological myofibroblasts. Future
studies are required to determine the relationship between EMT
and the involvement of FSCs in fibromatosis nodules. Applications
of this model include interventions in the clinical disease course,
understanding the signaling or molecular pathways responsible for
fibromatosis development, and identifying new therapeutic
strategies for the treatment of fibromatosis.
Our study showed that TGF-b1 can induce myofibroblast
differentiation of FSCs. Similar effects of TGF-b1 were reported in
myofibroblast development or activation in hepatic stellate cells
[38], mammary fibroblasts [39] or endothelial cells, renal tubular
epithelial cells [40], and neural crest stem cells [41]. A higher level
of TGF-b1 has been found in palmar fibromatosis [42] and penile
fibromatosis [43] compared with normal tissues. Because TGF-b1
is released after local trauma or after surgical excision [44], the
prevalence or recurrence of fibromatosis is associated with
previous trauma [45] and surgery history [2;13–15]. However,
the detailed mechanism by which the increase in endogenous
TGF-b1 production is involved in the development of fibromatosis
requires further investigation. Our study showing a response of
FSCs to TGF-b1 in vitro suggests that TGF-b1 plays a role in the
development and recurrence of fibromatosis.
FSCs from residual fibromatosis tissues may be stimulated to
induce myofibroblast differentiation and collagen deposition,
leading to the recurrence of fibromatosis. Given that radical
excision of fibromatosis is currently impossible, additional
strategies that target FSCs are needed to prevent progression or
recurrence after excision. Our study showed that TSA inhibited
the proliferation and differentiation of FSCs in vitro and that FSCs
pretreated in vivo with TSA did not undergo myofibroblast
differentiation and the Matrigel decomposed. Inhibition of
of adipogenic differentiation (AIM) in FSCs as demonstrated by RT-PCR. (D) Osteogenic potential of FSCs. Microscopic images showing Alizarin red-S
staining of control cells (Con) and osteogenic differentiation at 21 days (OIM). Expression of osteogenic genes after 7 days of osteogenic
differentiation (OIM) in FSCs as demonstrated by RT-PCR. (E) Chondrogenic potential of FSCs. Alcian blue staining and immunohistochemical staining
of type II collagen at 21 days of chondrogenic differentiation. Expression of chondrogenic genes after 7 days of chondrogenic differentiation (CIM) in
FSCs as demonstrated by RT-PCR. All experiments were repeated with FSCs from three different donors. All experiments were performed with FSCs at
passages 5–8. The non-stem cell lines 293T cells were used as negative control cells. Bars=100 mm. (Con: no induction control).
doi:10.1371/journal.pone.0024050.g003
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PLoS ONE | www.plosone.org 9 August 2011 | Volume 6 | Issue 8 | e24050myofibroblast differentiation decreased type I collagen accumula-
tion. These data suggest that TSA is a potential adjuvant
treatment for fibromatosis that may inhibit the progression or
prevent recurrence.
In terms of the clinical applications of TSA, preclinical
investigations by several groups have reported the potential
efficacy of TSA in the treatment of liver fibrosis [23], breast
cancer [46], and squamous cell carcinoma [47]. TSA can inhibit
histone deacetylase at nanomolar concentrations, and the resulting
histone hyperacetylation leads to chromatin relaxation, causes cell
growth arrest [48], and inhibits proliferation [49]. TSA also has
been reported to inhibit gene expression of a-SMA and types III
and I collagen by inhibiting Sp1 [50;51]. Thus, TSA inhibited the
proliferation and myofibroblastic differentiation of FSCs, and our
results are consistent with this inhibitory ability. Our results
suggest that TSA may be useful when given as a local injection
into fibromatosis nodules before their progression to cords. Our
observation that TSA blocked the formation of fibromatosis
Figure 4. Formation of fibromatosis nodules by FSCs in vivo and expression of multiple fibrotic proteins at different stages. (A) FSCs
were delivered in Matrigel and implanted beneath the dorsal skin of nude mice. Nodule formation was seen at 14 days and involution at 56 days.
Small cubes: macroscopic views of the implants after 7, 14, 28, and 56 days in vivo. Scale=1 mm. H&E staining and immunofluorescence analysis of a-
SMA, types III and I collagen. Bars=50 mm. (B) The percentages of stained areas. (C) Western blotting for a-SMA, types III and I collagen. Data are
shown as mean 6 SD (n=3). Statistical significance is presented as **, p,0.01 compared with other groups. All experiments were repeated with FSCs
from three different donors.
doi:10.1371/journal.pone.0024050.g004
Figure 5. Formation of fibromatosis nodules by GFP-labeled FSCs in vivo. (A) FSCs were infected with a lentiviral vector carrying the GFP
gene. Images show the morphology and GFP fluorescence after selection for 7 days. (B–C) GFP-labeled FSCs were delivered in Matrigel and implanted
beneath the dorsal skin of nude mice. Microscopic views of the implants after 14 days. (B) Immunofluorescence for GFP (green), a-SMA (red), and
DAPI (blue). (Right panel) Absence of staining with the primary antibody for GFP and a-SMA was used as a negative control. (C) Sections were also
stained for GFP (green), type III collagen (red) and DAPI (blue). (Right panel) Absence of staining with the primary antibody for GFP and type III
collagen was used as a negative control. Bars=50 mm. All experiments were repeated with FSCs from three different donors.
doi:10.1371/journal.pone.0024050.g005
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may serve in preclinical trials for drug selection to treat
fibromatosis.
There remain some limitations to the use of this model that
require further clarification. For example, the fibromatosis nodules
in the model were created subcutaneously as opposed to the
progression of human fibromatosis nodules to fibromatosis cords,
which occurs only in specific areas such as the plantar or palmar
fascia. The cells used in this study were isolated from palmar
fibromatosis, a type of superficial fibromatosis, and future studies
are needed with models created by FSCs derived from deep
fibromatosis.
Figure 6. Inhibition by TSA of proliferation and differentiation of FSCs in vitro. (A) FSCs seeded at 2000 cells/well in 96-well plates were
treated with TSA at the indicated concentrations for 7 days. The IC50-value was measured. (B) FSCs were cultured in the presence of the indicated
concentration of TSA, and quantitative RT-PCR analysis was performed at 14 days. (C) Immunofluorescence for a-SMA and types III and I collagen.
FSCs were cultured with or without TSA, and immunofluorescence analysis was performed at 14 days. Bars=50 mm. (D) The percentages of stained
areas. (E) The percentages of myofibroblasts. Data are shown as mean 6 SD (n=3). Statistical significance is presented as **, p,0.01 compared with
other groups. All experiments were repeated with FSCs from three different donors.
doi:10.1371/journal.pone.0024050.g006
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PLoS ONE | www.plosone.org 12 August 2011 | Volume 6 | Issue 8 | e24050Conclusion
We have successfully isolated and identified the stem cells
involved in palmar fibromatosis. Our in vitro and in vivo studies
showed that FSCs can undergo myofibroblast differentiation with
time to undergo an involutive process involving type I collagen
accumulation. The application of FSCs may provide a promising
murine model to study the biological and pathological processes
responsible for development of fibromatosis nodules, which may
lead to therapeutic interventions for fibromatosis. For example,
TSA may be a potential therapy for fibromatosis. Understanding
the cellular origin of fibromatosis will also enable us to examine
the mechanisms underlying myofibroblast differentiation and to
delineate targets for adjuvant therapy.
Supporting Information
Figure S1 Nodule and cord of human palmar fibroma-
tosis. (A) H&E staining and immunofluorescence analysis of a-
SMA, types III and I collagen. Bars =50 mm. (B) The percentages
of stained areas. Data are shown as mean 6 SD (n=3). Statistical
significance is presented as **, p,0.01 compared with other
groups. All experiments were repeated from three different donors.
(TIF)
Figure S2 PCR for genomic DNA contamination in FSCs and
293T cells (A) after 14 days of hepatic differentiation (HIM), (B)
after 14 days of neuroglial differentiation (NIM), (C) after 7 days of
adipogenic differentiation (AIM), (D) after 7 days of osteogenic
differentiation (OIM), and (E) after 7 days of chondrogenic
differentiation (CIM). All experiments were repeated with FSCs
from three different donors. All experiments were performed with
FSCs at passage of 5–8. (Con: without induction).
(TIF)
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